Biosimulation, which involves computer-aided simulation of biological processes and systems, finds extensive applications in drug discovery and development. The biosimulation market, valued at $2.8 billion in 2022, is expected to experience robust growth at a CAGR of 16.9% from 2022 to 2030.
The company we are profiling today is Simulations Plus Inc. (SLP), a provider of AI-powered technology solutions to enhance drug discovery, development, research, and regulatory approval processes, accelerating a drug's journey from conception to market. Its customers include companies involved in pharmaceuticals, biotechnology, agrotechnology, and cosmetics, as well as universities, hospitals, and government research organizations.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.